Literature DB >> 7594081

Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population.

F Cecchi1, I Olivotto, A Montereggi, G Santoro, A Dolara, B J Maron.   

Abstract

OBJECTIVES: Our aim was to study a population of patients with hypertrophic cardiomyopathy from the well defined geographic region of Tuscany in central Italy, a group virtually free of selective referral bias and therefore probably closely representative of the true patient population with this disease.
BACKGROUND: Most available information on clinical course, natural history and prognosis of hypertrophic cardiomyopathy is based on data generated from tertiary referral centers and therefore constitutes a potentially biased perspective of the disease process in this complex and diverse condition.
METHODS: The study group comprised 202 patients aged 1 to 74 years (mean +/- SD 41 +/- 17) at initial diagnosis and followed up for 1 to 30 years (mean 10 +/- 5).
RESULTS: Largely with the use of single or multiple drug therapy, the vast majority of patients (n = 154 [76%]) were asymptomatic or mildly symptomatic and in stable or improved condition over the period of follow-up, whereas the remaining patients (n = 48 [24%]) experienced deterioration, had substantial functional impairment or died. Of the 13 patients (6%) who died of cardiovascular causes related to hypertrophic cardiomyopathy, 11 had progressive congestive heart failure (including 6 in the end-stage phase) and only 2 died suddenly. The annual mortality rate for cardiovascular disease was 0.6% and that due to sudden cardiac death was only 0.1%; the cumulative survival rate was 97%, 95% and 92%, respectively, at 5, 10 and 15 years of follow-up. Atrial fibrillation proved to be a relatively common (n = 57 [28%]) and particularly unfavorable clinical feature, with premature death occurring in 9 of the 57 patients. The cumulative survival rate after 15 years was 76% for patients with atrial fibrillation versus 97% for patients with sinus rhythm. Syncope occurred in 33 patients (16%) but did not appear to be of prognostic significance.
CONCLUSIONS: In an unselected regional population, hypertrophic cardiomyopathy had a relatively benign prognosis inconsistent with its prior characterization as a generally progressive disorder, based primarily on the experience of selected referral institutions. Sudden unexpected cardiac death was distinctly uncommon, although a sizable proportion of patients (particularly the subset prone to atrial fibrillation), did experience clinical deterioration.

Entities:  

Mesh:

Year:  1995        PMID: 7594081     DOI: 10.1016/0735-1097(95)00353-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  46 in total

Review 1.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death.

Authors:  William J McKenna; Elijah R Behr
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

Review 2.  Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.

Authors:  I Savelieva; A J Camm
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

3.  Clinical spectrum in a family with tropomyosin-mediated hypertrophic cardiomyopathy and sudden death in childhood.

Authors:  Majd Makhoul; Michael J Ackerman; Dianne L Atkins; Ian H Law
Journal:  Pediatr Cardiol       Date:  2010-11-19       Impact factor: 1.655

Review 4.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

5.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.

Authors:  Anna Axelsson Raja; Hoshang Farhad; Anne Marie Valente; John-Paul Couce; John Lynn Jefferies; Henning Bundgaard; Kenneth Zahka; Harry Lever; Anne M Murphy; Euan Ashley; Sharlene M Day; Mark V Sherrid; Ling Shi; David A Bluemke; Charles E Canter; Steven D Colan; Carolyn Y Ho
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

Review 6.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

Review 7.  The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome.

Authors:  J Burn; J Camm; M J Davies; L Peltonen; P J Schwartz; H Watkins
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

Review 8.  Sudden cardiac death in patients with nonischemic cardiomyopathy.

Authors:  Brian P Betensky; Sanjay Dixit
Journal:  Indian Heart J       Date:  2014-01-06

Review 9.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Hypertrophic cardiomyopathy in the Saudi Arabian population: Clinical and echocardiographic characteristics and outcome analysis.

Authors:  Waqas Ahmed; Naveed Akhtar; Odd Bech-Hanssen; Bader Al Mahdi; Talal Al Otaibi; Bahaa M Fadel
Journal:  J Saudi Heart Assoc       Date:  2013-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.